Collegium Pharmaceutical Announces Share Repurchase Agreement

Collegium Pharmaceutical ( (COLL) ) just unveiled an announcement.

On May 12, 2025, Collegium Pharmaceutical announced an accelerated share repurchase agreement with Jefferies LLC to buy back $25 million of its common stock as part of a $150 million share repurchase program authorized in January 2024. The agreement involves an initial delivery of 692,281 shares and will be settled based on the volume-weighted average prices of the stock, with final settlement expected by the third quarter of 2025. This move is likely to impact the company’s stock value and market positioning, reflecting a strategic financial decision to enhance shareholder value.

The most recent analyst rating on (COLL) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Collegium Pharmaceutical stock, see the COLL Stock Forecast page.

Spark’s Take on COLL Stock

According to Spark, TipRanks’ AI Analyst, COLL is a Outperform.

Collegium Pharmaceutical’s strong financial performance, highlighted by impressive revenue growth and solid cash management, drives the stock score. Despite high leverage, effective equity returns and strategic initiatives provide confidence. Technical analysis suggests cautious market sentiment, while reasonable valuation supports the stock’s potential. Positive earnings call sentiment further boosts the outlook, although increased expenses and portfolio pressures are challenges to monitor.

To see Spark’s full report on COLL stock, click here.

More about Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing innovative medications. The company is known for its work in pain management and has a market focus on providing solutions for patients and healthcare providers.

Average Trading Volume: 400,704

Technical Sentiment Signal: Sell

Current Market Cap: $928.6M

See more data about COLL stock on TipRanks’ Stock Analysis page.